ArcticZymes Technologies ASA

Equities

AZT

NO0010014632

Biotechnology & Medical Research

Real-time Oslo Bors Other stock markets 10:15:01 2024-04-29 am EDT			5-day change	1st Jan Change
26 ^NOK	0.00%		-0.76%	-38.21%

Apr. 09	Norway's ArcticZymes Teams Up With Austrian Group for Bionanoparticles Research Project	MT
Apr. 09	ArcticZymes Technologies ASA Initiates Joint Research Project with Austrian Centre of Industrial Biotechnology	CI

ArcticZymes Technologies ASA: Invitation to presentation of Q4 2023 results

January 29, 2024 at 03:10 am EST

The Company will host a Q4 2023 presentation for investors, analysts and media at 08:30 CET on Thursday, 1 February, 2024 at Høyres Hus, Stortingsgata 20, Oslo.

The presentation will be given by CEO, Michael Akoh, CFO, Børge Sørvoll and VP Corporate Development, Jeremy Gillespie.

The presentation can also be followed as a live webcast from Hegnar TV on https://channel.royalcast.com/landingpage/hegnarmedia/20240201_2/ or www.arcticzymes.com. It will be possible to post questions through the webcast console.

The report for Q4 and 12 months 2023 will be available on www.newsweb.no and on the company's homepage www.arcticzymes.com from 07.00 CET on Thursday, 1 February, 2024.

For further information, please contact:
CFO
Børge Sørvoll
borge.sorvoll@arcticzymes.com
+47 952 90187

https://news.cision.com/arcticzymes-technologies/r/arcticzymes-technologies-asa--invitation-to-presentation-of-q4-2023-results,c3897899

Latest news about ArcticZymes Technologies ASA

Norway's ArcticZymes Teams Up With Austrian Group for Bionanoparticles Research Project	Apr. 09	MT
ArcticZymes Technologies ASA Initiates Joint Research Project with Austrian Centre of Industrial Biotechnology	Apr. 09	CI
ArcticZymes Technologies ASA Announces Resignation of Edgar Koster as Board Member	Apr. 02	CI
ArcticZymes Technologies ASA Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Feb. 01	CI
ArcticZymes Technologies ASA Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 01	CI
Transcript : ArcticZymes Technologies ASA, Q4 2023 Earnings Call, Feb 01, 2024	Feb. 01
Arcticzymes Technologies Asa Announces the Launch of Its First Gmp-Grade Product, San Hq	Jan. 30	CI
Norway’s ArcticZymes Technologies Manufactures GMP-grade Enzyme	Jan. 30	MT
ArcticZymes Technologies ASA Launches T7 RNA Polymerase	Dec. 21	CI
ArcticZymes Technologies ASA Enters into an Agreement with Biomatter	Dec. 19	CI
ArcticZymes Technologies ASA Announces Partnership with Biomatter	Dec. 19	CI
ArcticZymes Technologies ASA Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 02	CI
Transcript : ArcticZymes Technologies ASA, Q3 2023 Earnings Call, Nov 02, 2023	Nov. 02
ArcticZymes Technologies' Wins US FDA's Filing Type 2 Status for Enzyme	23-09-21	MT
ArcticZymes Technologies ASA Announces DMF for SAN HQ GMP accepted by the US FDA	23-09-21	CI
ArcticZymes Technologies ASA(OB:AZT) dropped from S&P Global BMI Index	23-09-18	CI
Transcript : ArcticZymes Technologies ASA, Q2 2023 Earnings Call, Aug 17, 2023	23-08-17
ArcticZymes Technologies ASA Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-16	CI
ArcticZymes Technologies ASA Launches Taq?? DNA Polymerase	23-08-09	CI
ArcticZymes Technologies Appoints New CEO	23-07-17	MT
ArcticZymes Technologies ASA Appoints Michael Akoh as Chief Executive Officer, Will Commence His Position No Later Than 1 November 2023	23-07-17	CI
ArcticZymes Technologies Files DMF for SAN HQ GMP	23-06-29	CI
Transcript : ArcticZymes Technologies ASA, Q1 2023 Earnings Call, May 04, 2023	23-05-04
ArcticZymes Technologies ASA Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-04	CI
ArcticZymes Technologies ASA Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-04	CI

Chart ArcticZymes Technologies ASA

Duration

Period

More charts

Company Profile

Arcticzymes Technologies ASA is a Norway-based holding company providing support functions to the ArcticZymes AS subsidiary including distribution, administration, finance, Information Technology (IT) and quality assurance. As a life science company, Arcticzymes Technologies ASA is focused on the development, manufacturing, and commercialization of novel and high-quality recombinant enzymes for use in molecular research, In Vitro Diagnostics (IVD) and biomanufacturing. Some of the key features of the Companyâs enzymes include cold activeness and salt tolerance. The Companyâs divided into two operating segments; Enzymes and Corporate. Arcticzymes established logistic hubs in the United States and the Netherlands to serve its customers more efficiently.

Sector

Biotechnology & Medical Research

Calendar

2024-05-07 - Q1 2024 Earnings Call

More about the company

Income Statement Evolution

More financial data

Ratings for ArcticZymes Technologies ASA

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

HOLD

Number of Analysts

Last Close Price

26 NOK

Average target price

32 NOK

Spread / Average Target

+23.08%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
ARCTICZYMES TECHNOLOGIES ASA	-38.21%	120M
IQVIA HOLDINGS INC.	+1.89%	42.75B
LONZA GROUP AG	+47.64%	41.61B
MODERNA, INC.	+11.49%	41.34B
CELLTRION, INC.	-12.36%	26.59B
ICON PUBLIC LIMITED COMPANY	+7.92%	25.49B
ALNYLAM PHARMACEUTICALS, INC.	-23.94%	18.12B
MEDPACE HOLDINGS, INC.	+29.58%	12.24B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-1.96%	11.76B
UNITED THERAPEUTICS CORPORATION	+7.69%	11B

Other Biotechnology & Medical Research